Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol

Therapeutic Drug Monitoring

Volumn 23, Issue 4, 2001, Pages 363-368

  Suzuki, Yutaro ^a   Someya, Toshiyuki ^a   Shimoda, Kazutaka ^b   Hirokane, Genta ^b   Morita, Sachiyo ^b   Yokono, Aya ^b   Inoue, Yoshimasa ^c   Takahashi, Saburo ^d  

^a NIIGATA UNIVERSITY   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c Welfide Corporation   (Japan)

^d Saitama Kounan Hospital   (Japan)

Author keywords

Chlorpromazine; Cytochrome P450 (CYP) 2D6; Drug interaction; Haloperidol

Indexed keywords

CHLORPROMAZINE; CYTOCHROME P450 2D6; HALOPERIDOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MIXTURE; GENOTYPE; HUMAN; JAPAN; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GENOTYPE; HALOPERIDOL; HUMANS; MIDDLE AGED; SCHIZOPHRENIA;

EID: 0034897146     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200108000-00007     Document Type: Article

References (26)

1. On the metabolism of haloperidol
2. Haloperidol reductase in human and guinea pig livers
3. Oxidation of reduced haloperidol to haloperidol: Involvement of human P450IID6 (sparteine/debrisoquine monooxygenase)
4. Use of antisera in the isolation of human specific conjugate of haloperidol
5. Studies on the conversion of haloperidol and its tetrahydropyridine dehaydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes
6. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia
7. The drug-drug interaction effects of haloperidol on plasma carbamazepine levels
8. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: In vivo evidence of the involvement of CYP3A4 for haloperidol metabolism
9. Drug interaction: Inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man
10. Debrisoquine oxidation phenotype during neuroleptic monotherapy
11. In vitro inhibition studies of two isozymes of human liver cytochrome P-450: Mephenytoin p-hydroxylase and sparteine monooxygenase
12. Substantial rise in sparteine metabolic ratio during haloperidol treatment
13. Haloperidol disposition is dependent on debrisoquine hydroxytation phenotype
14. Effect of quinidine on the interconversion kinetics between hatoperidol and reduced haloperidol in humans: Implications for the involvement of cytochrome P450IID6
15. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients
16. Genotyping of poor metabolizers of debrisoquine by alle-specific PCR amplification
17. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology
18. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
19. Determination of bromperidol in serum by automated column-switching high performance liquid chromatography
20. Interethnic differences in drug metabolism: Influence of genetic and environmental factors on debrisoquine hydroxylation phenotype
21. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
22. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): Evidence for two major allozymes in extensive metabolizers
23. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
24. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine
25. Coadministration of fluvoxamine increases serum concentration of haloperidol